Hans Hammers
University of Texas Southwestern Medical Center
H-index: 61
North America-United States
Top articles of Hans Hammers
Title | Journal | Author(s) | Publication Date |
|---|---|---|---|
Advanced renal cell cancer combination immunotherapy clinical trial (ARCITECT; HCRN GU 22-587). | Michael Thomas Serzan Opeyemi Jegede Mehmet Asim Bilen David A Braun David Johnson Einstein | 2024/2/1 | |
Abstract LB257: Possible involvement of PDL1 intrinsic signaling to acquired resistance to immunotherapy for renal cell carcinoma (RCC) | Cancer Research | Jin-Sung Chung Lei Guo Vinita Popat Ponciano D Cruz Lin Xu | 2024/4/5 |
The 5th Kidney Cancer Research Summit: Research Accelerating Cures for Renal Cell Carcinoma in 2023 | The Oncologist | Toni K Choueiri Sumanta K Pal Bryan Lewis Susan Poteat Kevin Pels | 2024/2/1 |
Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled … | Nourhan El Ahmar Sayed Matar Opeyemi Jegede Yasmin Nabil Laimon Varunika Savla | 2024/2/1 | |
Renal cell carcinoma histologic subtypes exhibit distinct transcriptional profiles | The Journal of Clinical Investigation | Pedro Barata Shuchi Gulati Andrew Elliott Hans J Hammers Earle F Burgess | 2024/4/23 |
Immunomodulatory response to neoadjuvant nivolumab in non-metastatic clear cell renal cell carcinoma | Scientific reports | Nirmish Singla Thomas R Nirschl Aleksandar Z Obradovic Eugene Shenderov Kara Lombardo | 2024/1/17 |
Nivolumab plus ipilimumab (NIVO+ IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): Long-term follow-up data from the phase 3 CheckMate … | Nizar M Tannir Bernard Escudier David F McDermott Mauricio Burotto Toni K Choueiri | 2024/2/1 | |
Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma | New England Journal of Medicine | Toni K Choueiri Piotr Tomczak Se Hoon Park Balaji Venugopal Tom Ferguson | 2024/4/18 |
Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A) | Journal for Immunotherapy of Cancer | Michael B Atkins Opeyemi A Jegede Naomi B Haas David F Mcdermott Mehmet A Bilen | 2024 |
A multi-center, open-label phase II study of lenvatinib plus pembrolizumab (LEAP) in patients with renal cell carcinoma with brain metastasis previously treated with immune … | Elshad Hasanov Hans J Hammers Daniel J George Brian I Rini Katy Beckermann | 2024/2/1 | |
Validation of the Lung Immune Prognostic Index (LIPI) as a prognostic biomarker in metastatic renal cell carcinoma | European Journal of Cancer | Lucía Carril-Ajuria Pernelle Lavaud Cecile Dalban Sylvie Negrier Gwénaëlle Gravis | 2024/4/8 |
Association of radiographic and pathologic outcomes in patients (pts) with advanced renal cell carcinoma (RCC) with and without thrombus receiving preoperative immune … | Wadih Issa Damla Gunenc Song Zhang Qinhan Zhou Thomas Gerald | 2024/2/1 | |
Abstract CT099: NGM707 in combination with pembrolizumab in advanced or metastatic solid tumors: Preliminary results from dose escalation | Cancer Research | Judy S Wang Manish R Sharma William J Edenfield Kartik Sehgal Do-Youn Oh | 2024/4/5 |
Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) | Journal for immunotherapy of cancer | Michael B Atkins Opeyemi A Jegede Naomi B Haas David F McDermott Mehmet A Bilen | 2023 |
Treatment for RCC: Educating Patients on Followup and Adverse Events. | Cancer Network | Hans Hammers | 2023/3/21 |
Extracranial palliative radiotherapy for metastatic renal cell carcinoma. | Young Suk Kwon Eric Hsu Maggie Stein Alana Christie Aurelie Garant | 2023/6/1 | |
1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell carcinoma | Miya Hugaboom Kelly Street Neil Ruthen Lena Wirth Opeyemi A Jegede | 2023/11/1 | |
Association of body mass index with the safety profile of nivolumab with or without ipilimumab | JAMA oncology | Jennifer L McQuade Hans Hammers Helena Furberg Andreas Engert Thierry André | 2023/1/1 |
Healthcare Professional Perspectives on Diagnosing RCC. | Cancer Network | Hans Hammers | 2023/3/21 |
Determinants of resistance to nivolumab (nivo) monotherapy investigated through genomic and transcriptomic analysis of renal cell carcinoma (RCC) tumors from the HCRN GU16-260 … | David A Braun Kelly Street Opeyemi Jegede Neil Ruthen Miya Hugaboom | 2023/6/1 |
